Our findings were consistent with ORR4 (57.3% in the BV arm) reported in the Alcanza trial, which also used IRF assessment as the primary endpoint,20 phase 2 studies of BV in CTCL (70%–73%),18, 19 and a recent Spanish registry, which reported an ORR of 67% in patients with advanced‐stage MF and CD30 LPDs.23 The gene discussed is TNFRSF8; the disease is mycosis fungoides.